Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
about
Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumesPractical characteristics of adaptive design in phase 2 and 3 clinical trials.Challenges to develop novel anti-inflammatory and analgesic drugs.The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation.
P2860
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Oral administration of GLPG025 ...... controlled, multicentre trial.
@en
Oral administration of GLPG025 ...... controlled, multicentre trial.
@nl
type
label
Oral administration of GLPG025 ...... controlled, multicentre trial.
@en
Oral administration of GLPG025 ...... controlled, multicentre trial.
@nl
prefLabel
Oral administration of GLPG025 ...... controlled, multicentre trial.
@en
Oral administration of GLPG025 ...... controlled, multicentre trial.
@nl
P2093
P1476
Oral administration of GLPG025 ...... -controlled, multicentre trial
@en
P2093
Annegret Van der Aa
Evgeny L Nasonov
Filip De Keyser
Florence Namour
Frédéric Vanhoutte
Johan Beetens
Patrick Durez
Piet Wigerinck
René Westhovens
P304
P356
10.1136/ANNRHEUMDIS-2012-202221
P407
P577
2012-11-17T00:00:00Z